These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 3308409)
1. l-Carnitine. A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism. Goa KL; Brogden RN Drugs; 1987 Jul; 34(1):1-24. PubMed ID: 3308409 [TBL] [Abstract][Full Text] [Related]
2. l-carnitine: Nutrition, pathology, and health benefits. Alhasaniah AH Saudi J Biol Sci; 2023 Feb; 30(2):103555. PubMed ID: 36632072 [TBL] [Abstract][Full Text] [Related]
3. [Stereopharmacology of carnitine]. Spasov AA; IIezhitsa IN Ross Fiziol Zh Im I M Sechenova; 2005 Dec; 91(12):1469-80. PubMed ID: 16493928 [TBL] [Abstract][Full Text] [Related]
4. New genetic defects in mitochondrial fatty acid oxidation and carnitine deficiency. Stanley CA Adv Pediatr; 1987; 34():59-88. PubMed ID: 3318304 [TBL] [Abstract][Full Text] [Related]
5. The therapeutic potential of carnitine in cardiovascular disorders. Pepine CJ Clin Ther; 1991; 13(1):2-21; discussion 1. PubMed ID: 2029724 [TBL] [Abstract][Full Text] [Related]
6. [Physiologic bases for the use of L-carnitine in cardiology]. Krähenbühl S Praxis (Bern 1994); 1998 Jan; 87(4):102-7. PubMed ID: 9522639 [TBL] [Abstract][Full Text] [Related]
7. [L-carnitine: metabolism, functions and value in pathology]. Jacob C; Belleville F Pathol Biol (Paris); 1992 Nov; 40(9):910-9. PubMed ID: 1296165 [TBL] [Abstract][Full Text] [Related]
9. Improvement of myocardial fatty acid metabolism through L-carnitine administration to chronic hemodialysis patients. Sakurabayashi T; Takaesu Y; Haginoshita S; Takeda T; Aoike I; Miyazaki S; Koda Y; Yuasa Y; Sakai S; Suzuki M; Takahashi S; Hirasawa Y; Nakamura T Am J Nephrol; 1999; 19(4):480-4. PubMed ID: 10460938 [TBL] [Abstract][Full Text] [Related]
10. The role of carnitine in myocardial dysfunction. Pauly DF; Pepine CJ Am J Kidney Dis; 2003 Apr; 41(4 Suppl 4):S35-43. PubMed ID: 12751052 [TBL] [Abstract][Full Text] [Related]
11. [The effect of L-carnitine on ischemic heart disease: experimental results]. Lerch R Praxis (Bern 1994); 1998 Jan; 87(4):97-100. PubMed ID: 9522638 [TBL] [Abstract][Full Text] [Related]
12. L-Carnitine: therapeutic applications of a conditionally-essential amino acid. Kelly GS Altern Med Rev; 1998 Oct; 3(5):345-60. PubMed ID: 9804680 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Ferrari R; Merli E; Cicchitelli G; Mele D; Fucili A; Ceconi C Ann N Y Acad Sci; 2004 Nov; 1033():79-91. PubMed ID: 15591005 [TBL] [Abstract][Full Text] [Related]
14. Levocarnitine and dialysis: a review. Schreiber B Nutr Clin Pract; 2005 Apr; 20(2):218-43. PubMed ID: 16207659 [TBL] [Abstract][Full Text] [Related]
15. L-carnitine administration in coronary artery disease and cardiomyopathy. Singh RB; Aslam M J Assoc Physicians India; 1998 Sep; 46(9):801-5. PubMed ID: 11229253 [TBL] [Abstract][Full Text] [Related]
16. The use of carnitine in pediatric nutrition. Crill CM; Helms RA Nutr Clin Pract; 2007 Apr; 22(2):204-13. PubMed ID: 17374794 [TBL] [Abstract][Full Text] [Related]
17. In vivo stable isotope studies in three patients affected with mitochondrial fatty acid oxidation disorders: limited diagnostic use of 1-13C fatty acid breath test using bolus technique. Jakobs C; Kneer J; Martin D; Boulloche J; Brivet M; Poll-The BT; Saudubray JM Eur J Pediatr; 1997 Aug; 156 Suppl 1():S78-82. PubMed ID: 9266222 [TBL] [Abstract][Full Text] [Related]
18. Carnitine in the treatment of valproic acid-induced toxicity. Lheureux PE; Hantson P Clin Toxicol (Phila); 2009 Feb; 47(2):101-11. PubMed ID: 19280426 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of L-carnitine. Evans AM; Fornasini G Clin Pharmacokinet; 2003; 42(11):941-67. PubMed ID: 12908852 [TBL] [Abstract][Full Text] [Related]
20. Combined therapy with PPARalpha agonist and L-carnitine rescues lipotoxic cardiomyopathy due to systemic carnitine deficiency. Asai T; Okumura K; Takahashi R; Matsui H; Numaguchi Y; Murakami H; Murakami R; Murohara T Cardiovasc Res; 2006 Jun; 70(3):566-77. PubMed ID: 16546150 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]